HAIKOU CITY, China, April 30 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it has retained ICR to advise the Company on investor communications best-practices in the U.S. capital markets.
Ms. Zhilin Li, President and CEO of China Pharma, stated, "Our decision to hire ICR is part of our overall effort to strengthen our management and advisory team in preparation for future growth. The healthcare industry in China is evolving rapidly and we particularly liked their focus on Asia, China's healthcare industry and their global support based in China and the U.S."
ICR has offices in Beijing, Shanghai, New York, Westport, Boston and Los Angeles and is comprised exclusively of seasoned Wall Street professionals -- former senior sell-side analysts, portfolio managers, investment bankers and capital markets professionals -- who possess invaluable experience in the capital markets.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by a scalable GMP-certified manufacturing infrastructure. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Medicine & Bio-pharmaceutical Co., Ltd (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Hold
|SOURCE China Pharma Holdings, Inc.|
Copyright©2009 PR Newswire.
All rights reserved